3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Glioma
3
Glioblastoma
3
Lung Neoplasms
2
Astrocytoma
2
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Mesothelioma
1
Ependymoma
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
aldesleukin
2
Trastuzumab
2
Pharmaceutical Preparations
2
Interleukin-2
2
Carboplatin
2
Bevacizumab
2
tocilizumab
1
tipifarnib
1
romidepsin
1
lipoplatin
1
Verteporfin
1
Valacyclovir
1
Tyrosine Kinase Inhibitors
1
Sorafenib
1
SPI-77, liposomal
1
Povidone-Iodine
1
Pleurodesis
1
Photochemotherapy
1
Paclitaxel
1
LMB-100
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Immunotherapy, Adoptive
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Decitabine
1
Dasatinib
1
Cytoreduction Surgical Procedures
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Pleural Effusion, Malignant
×
Valacyclovir
×
Clear all
NCT01997190
2023-08-25
MpeTK01
Candel Therapeutics, Inc.
Phase 1
Completed
19 enrolled